Evidence map›Paper›PMID 30193128›Full record

ArticleCell stem cell2018

Revert the SIRT: Normalizing SIRT1 Activity in Myelodysplastic Stem Cells.

Fabrizio Simeoni, Tim C P Somervaille

Open access · bronzeAbstract readComment
PubMed Publisher
In one paragraph

Article in Cell stem cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Fabrizio SimeoniLeukaemia Biology Laboratory, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, M20 4JG, UK.
Tim C P SomervailleLeukaemia Biology Laboratory, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, M20 4JG, UK. Electronic address: tim.somervaille@cruk.manchester.ac.uk.
University of Manchester · GB

Funding

Cancer Research UK 19280
6 · The paper itself

Abstract

Myelodysplastic syndromes are hematologic malignancies with few treatment options and a propensity to transform to acute myeloid leukemia. In this issue of Cell Stem Cell, Sun et al. (2018) report that low SIRT1 levels in myelodysplastic stem cells contribute to aberrant self-renewal through enabling hyperacetylation and reduced activity of TET2.

Indexed as

Hematologic NeoplasmsLeukemia, Myeloid, AcuteMyelodysplastic SyndromesDioxygenasesDNA-Binding ProteinsHumansProto-Oncogene ProteinsSirtuin 1Stem CellsDioxygenasesDNA-Binding ProteinsProto-Oncogene ProteinsSIRT1 protein, humanSirtuin 1TET2 protein, human

Identifiers

PMID30193128
OpenAlexW2889761177

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.